

# Francisco Marin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1075217/publications.pdf>

Version: 2024-02-01

253  
papers

8,525  
citations

41258

49  
h-index

54797

84  
g-index

262  
all docs

262  
docs citations

262  
times ranked

8694  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society  | 1.0 | 490       |
| 2  | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.   | 1.8 | 292       |
| 3  | Morphological Fate of Rhombomeres in Quail/Chick Chimeras: A Segmental Analysis of Hindbrain Nuclei. <i>European Journal of Neuroscience</i> , 1995, 7, 1714-1738.   | 1.2 | 280       |
| 4  | Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..   | 1.8 | 234       |
| 5  | Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions   | 1.0 | 216       |
| 6  | 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. <i>Europace</i> , 2019, 21, 192-193. | 0.7 | 209       |
| 7  | Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 55-60.  | 0.7 | 204       |
| 8  | Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.  | 0.7 | 197       |
| 9  | Patterning of the Embryonic Avian Midbrain after Experimental Inversions: A Polarizing Activity from the Isthmus. <i>Developmental Biology</i> , 1994, 163, 19-37.   | 0.9 | 190       |
| 10 | Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1189-1198.   | 1.8 | 182       |
| 11 | Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a Real-World Population With Atrial Fibrillation Receiving Anticoagulant Therapy. <i>Chest</i> , 2013, 143, 179-184.  | 0.4 | 176       |
| 12 | The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2199-2204.   | 1.2 | 171       |
| 13 | Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3421-3429.  | 5.4 | 153       |
| 14 | Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.  | 0.7 | 124       |
| 15 | Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 312-318.   | 2.1 | 123       |
| 16 | Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2496-2504.   | 1.2 | 121       |
| 17 | Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. <i>European Heart Journal</i> , 2003, 24, 1373-1380.  | 1.0 | 118       |
| 18 | Contemporary stroke prevention strategies in 11% of European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.  | 0.7 | 118       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.   | 0.4 | 117       |
| 20 | SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 1083-1088.  | 0.6 | 112       |
| 21 | Renal Impairment in a "Real-Life" Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). <i>American Journal of Cardiology</i> , 2013, 111, 1159-1164.   | 0.7 | 110       |
| 22 | Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 956-960.   | 1.8 | 102       |
| 23 | High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1500-1507.  | 1.9 | 97        |
| 24 | Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. <i>Stroke</i> , 2003, 34, 1181-1186.   | 1.0 | 93        |
| 25 | A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. <i>Journal of Internal Medicine</i> , 2007, 262, 651-658.  | 2.7 | 87        |
| 26 | Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes. <i>Atherosclerosis</i> , 2013, 227, 313-322.  | 0.4 | 87        |
| 27 | Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. <i>Journal of Nephrology</i> , 2020, 33, 737-745.  | 0.9 | 81        |
| 28 | Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. <i>Heart</i> , 2004, 90, 1162-1166.   | 1.2 | 80        |
| 29 | Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 85-91.   | 1.2 | 80        |
| 30 | Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. <i>Basic Research in Cardiology</i> , 2011, 106, 911-923.  | 2.5 | 80        |
| 31 | Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1448-1454.   | 1.8 | 74        |
| 32 | Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.   | 0.7 | 74        |
| 33 | European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8. | 0.7 | 72        |
| 34 | Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. <i>Thrombosis and Haemostasis</i> , 2011, 106, 569-571.  | 1.8 | 70        |
| 35 | Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. <i>European Journal of Internal Medicine</i> , 2016, 35, 89-94.  | 1.0 | 68        |
| 36 | Quality of Anticoagulation With Vitamin K Antagonists. <i>Clinical Cardiology</i> , 2015, 38, 357-364.  | 0.7 | 67        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 296-303.   | 1.2 | 65        |
| 38 | Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 459-466.  | 1.4 | 60        |
| 39 | The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1080-1087.  | 1.8 | 60        |
| 40 | Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification. <i>FASEB Journal</i> , 2018, 32, 4459-4469.  | 0.2 | 60        |
| 41 | Hypofibrinolysis in atrial fibrillation. <i>American Heart Journal</i> , 1998, 136, 956-960.   | 1.2 | 59        |
| 42 | The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.   | 1.8 | 57        |
| 43 | Long-term bleeding risk prediction in "real world"™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.  | 1.8 | 56        |
| 44 | The future of nutrition: Nutrigenomics and nutrigenetics in obesity and cardiovascular diseases. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 3030-3041.  | 5.4 | 54        |
| 45 | The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-world"™ Inception Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1237-1243.   | 0.6 | 51        |
| 46 | Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2261-2266.   | 1.8 | 51        |
| 47 | Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRs) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 235-250. | 1.4 | 50        |
| 48 | Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.  | 1.2 | 49        |
| 49 | Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 40378.   | 1.6 | 48        |
| 50 | Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.  | 1.0 | 48        |
| 51 | Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.   | 0.7 | 47        |
| 52 | Invasive strategy and frailty in very elderly patients with acute coronary syndromes. <i>EuroIntervention</i> , 2018, 14, e336-e342.   | 1.4 | 46        |
| 53 | Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. <i>European Journal of Internal Medicine</i> , 2012, 23, 169-174.  | 1.0 | 45        |
| 54 | Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13436.  | 1.7 | 45        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 932-939.   | 1.0 | 44        |
| 56 | Long-term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA <sub>2</sub> DS <sub>2</sub> -VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .   | 1.6 | 42        |
| 57 | Valor predictivo de la escala CHA <sub>2</sub> DS <sub>2</sub> -VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 627-633.   | 0.6 | 41        |
| 58 | Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1200-1207.  | 1.8 | 41        |
| 59 | Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 696-701.  | 1.0 | 39        |
| 60 | Quality of oral anticoagulation with vitamin K antagonists in "real-world" patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.  | 0.7 | 39        |
| 61 | Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 348-357.  | 0.4 | 39        |
| 62 | Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 749-757.   | 0.4 | 38        |
| 63 | Biomarkers in atrial fibrillation: an overview. <i>International Journal of Clinical Practice</i> , 2014, 68, 434-443.   | 0.8 | 37        |
| 64 | Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 699-704.   | 0.9 | 36        |
| 65 | Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-788.   | 1.8 | 36        |
| 66 | Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEL, SECOT and AEU. <i>Revista Espanola De Cardiologia (English Ed)</i> 2020, 73, 749-757. | 0.4 | 35        |
| 67 | Fibrinolytic function and atrial fibrillation. <i>Thrombosis Research</i> , 2003, 109, 233-240.  | 0.8 | 34        |
| 68 | Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. <i>Journal of Cardiac Failure</i> , 2008, 14, 414-419.  | 0.7 | 33        |
| 69 | Î <sup>2</sup> -Trace Protein: From GFR Marker to Cardiovascular Risk Predictor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 873-881.  | 2.2 | 32        |
| 70 | Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.   | 1.6 | 31        |
| 71 | Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRIL Clinical Trial Study Design. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 154-159.   | 0.4 | 31        |
| 72 | En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificación del posicionamiento terapéutico UT/V4/23122013. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 551-553.   | 0.6 | 28        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.                                  | 1.4 | 28        |
| 74 | Nuevas evidencias, nuevas controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad Europea de Cardiología. Revista Española De Cardiología, 2012, 65, 7-13.                                      | 0.6 | 26        |
| 75 | Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace, 2020, 22, 162-169. | 0.7 | 26        |
| 76 | The impact of statin use on atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 845-861.   | 0.2 | 25        |
| 77 | Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology, 2022, 111, 70-84.                          | 1.5 | 25        |
| 78 | Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. American Journal of Cardiology, 1999, 84, 862-864.   | 0.7 | 24        |
| 79 | Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.   | 1.0 | 24        |
| 80 | Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 62, 48-53.   | 1.0 | 24        |
| 81 | Effect of Statins on Preventing Recurrence of Atrial Fibrillation After Electrical Cardioversion. American Journal of Cardiology, 2006, 98, 1299-1300.   | 0.7 | 23        |
| 82 | Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. International Journal of Clinical Practice, 2009, 63, 1465-1471.                                     | 0.8 | 23        |
| 83 | Enhancing the "real world" prediction of cardiovascular events and major bleeding with the CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.                                  | 1.5 | 22        |
| 84 | Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Medicine, 2021, 19, 256.             | 2.3 | 22        |
| 85 | Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. European Journal of Clinical Investigation, 2012, 42, 1302-1308.  | 1.7 | 21        |
| 86 | Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. Circulation Journal, 2016, 80, 2102-2108.   | 0.7 | 21        |
| 87 | Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.   | 1.1 | 21        |
| 88 | Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 57-65.  | 1.0 | 21        |
| 89 | Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 521-530.  | 1.0 | 20        |
| 90 | The prognostic role of the adiponectin levels in atrial fibrillation. European Journal of Clinical Investigation, 2013, 43, 168-173.   | 1.7 | 20        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Tratamiento antiarrátmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIA. Revista Espanola De Cardiologia, 2016, 69, 54-60.  | 0.6 | 20        |
| 92  | sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. European Journal of Clinical Investigation, 2015, 45, 899-905.   | 1.7 | 19        |
| 93  | Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. Journal of Atherosclerosis and Thrombosis, 2015, 22, 610-617.  | 0.9 | 19        |
| 94  | The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thrombosis and Haemostasis, 2015, 113, 671-673.   | 1.8 | 19        |
| 95  | Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.   | 0.7 | 19        |
| 96  | Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 61, 48-53.  | 1.0 | 19        |
| 97  | Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.  | 1.2 | 18        |
| 98  | GDF-15 and risk stratification in atrial fibrillation. Nature Reviews Cardiology, 2015, 12, 8-9.  | 6.1 | 18        |
| 99  | The SAME-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.   | 0.6 | 18        |
| 100 | Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in "real-world" atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.                                    | 0.8 | 18        |
| 101 | "Real-world" observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.                    | 0.7 | 18        |
| 102 | Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thrombosis Research, 2021, 205, 1-7.  | 0.8 | 18        |
| 103 | Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 497-504.   | 0.4 | 17        |
| 104 | Comparison of Risk Prediction With the <sc>CKD&EPI</sc> and <sc>MDRD</sc> Equations in Non&sc>ST</sc> Segment Elevation Acute Coronary Syndrome. Clinical Cardiology, 2016, 39, 507-515.  | 0.7 | 17        |
| 105 | Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.  | 1.6 | 16        |
| 106 | Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft&Gault, Modification of Diet in Renal Disease&4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, . | 1.6 | 16        |
| 107 | Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.   | 1.2 | 16        |
| 108 | An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. Chest, 2011, 139, 1402-1409.   | 0.4 | 15        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 49-58.   | 2.7 | 15        |
| 110 | Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 1382-1387.  | 0.7 | 15        |
| 111 | Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 583-593.  | 0.6 | 15        |
| 112 | Factor VII $\epsilon$ 323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. <i>Annals of Medicine</i> , 2008, 40, 553-559.  | 1.5 | 14        |
| 113 | Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 627-633.  | 0.4 | 14        |
| 114 | Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 613-621.                                | 0.2 | 14        |
| 115 | Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018, 33, 847-854.   | 1.3 | 14        |
| 116 | High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2019, 175, 95-101.   | 0.8 | 14        |
| 117 | Carga de comorbilidad y beneficio de la revascularizaci3n en ancianos con s3ndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 765-772.   | 0.6 | 14        |
| 118 | Novel insights in the relationship of gut microbiota and coronary artery diseases. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 3738-3750.   | 5.4 | 14        |
| 119 | Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009, 132, 227-232.   | 0.8 | 13        |
| 120 | Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. <i>Thrombosis and Haemostasis</i> , 2012, 107, 51-58.   | 1.8 | 13        |
| 121 | A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.  | 0.8 | 13        |
| 122 | A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. <i>Drug Metabolism Reviews</i> , 2015, 47, 388-400.  | 1.5 | 13        |
| 123 | CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. <i>Annals of Medicine</i> , 2010, 42, 439-446.   | 1.5 | 12        |
| 124 | Interleucina 6 y prote3na C reactiva ultrasensible para la predicci3n de la evoluci3n cl3nica en s3ndromes coronarios agudos sin elevaci3n del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 185-192.   | 0.6 | 12        |
| 125 | $\beta$ 2-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. <i>Chest</i> , 2013, 144, 1564-1570.  | 0.4 | 12        |
| 126 | Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated $\epsilon$ Real-World $\epsilon$ in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792. | 0.7 | 12        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. <i>Oncotarget</i> , 2017, 8, 80182-80191.  | 0.8 | 12        |
| 128 | Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.  | 0.7 | 12        |
| 129 | Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2006, 59, 537-544.  | 0.4 | 11        |
| 130 | Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 185-192.  | 0.4 | 11        |
| 131 | Comparative Determination and Monitoring of Biomarkers of Necrosis and Myocardial Remodeling between Radiofrequency Ablation and Cryoablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 31-36.   | 0.5 | 11        |
| 132 | Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. <i>Thrombosis and Haemostasis</i> , 2013, 110, 623-625.   | 1.8 | 11        |
| 133 | CALU polymorphism A29809G affects calumenin availability involving vascular calcification. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 82, 218-227.   | 0.9 | 11        |
| 134 | Comentarios a la guÃa ESC 2016 sobre el diagnÃstico y tratamiento de la fibrilaciÃn auricular. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 2-8.  | 0.6 | 11        |
| 135 | Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.   | 1.0 | 11        |
| 136 | Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871. | 0.7 | 11        |
| 137 | Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010, 42, 562-575.  | 1.5 | 10        |
| 138 | On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 551-553.   | 0.4 | 10        |
| 139 | Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 696-703.   | 0.4 | 10        |
| 140 | Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.   | 0.7 | 10        |
| 141 | Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for) Tj ETQq1 1 0.784314. <a href="#">https://doi.org/10.1093/eurheartj/ehab100</a>  | 0.7 | 10        |
| 142 | Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021, 20, 176.  | 2.7 | 10        |
| 143 | Novel biomarkers in cardiology: MicroRNAs in atrial fibrillation. <i>Archivos De Cardiologia De Mexico</i> , 2015, 85, 225-229.   | 0.1 | 10        |
| 144 | An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy. <i>Medicinal Chemistry</i> , 2011, 7, 275-285.  | 0.7 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.  | 1.7 | 10        |
| 146 | The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322. | 0.7 | 9         |
| 147 | Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 715.  | 1.0 | 9         |
| 148 | Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.   | 0.7 | 9         |
| 149 | Fracción aminoterminal del péptido natriurético cerebral y troponina ultrasensible en el dolor torácico agudo de origen incierto. Un subestudio del estudio PITAGORAS. <i>Revista Española De Cardiología</i> , 2013, 66, 532-538.   | 0.6 | 8         |
| 150 | Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.  | 1.4 | 8         |
| 151 | Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs clinical-trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 282-289.   | 1.1 | 8         |
| 152 | In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database. <i>Cardiology Journal</i> , 2021, 28, 589-597.   | 0.5 | 8         |
| 153 | Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 67-77.   | 0.9 | 7         |
| 154 | Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. <i>Annals of Medicine</i> , 2020, 52, 300-309.   | 1.5 | 7         |
| 155 | Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7113.  | 1.8 | 7         |
| 156 | Effects of atorvastatin 80 mg daily on indices of matrix remodelling in high-risk patients with ischemic heart disease. <i>International Journal of Cardiology</i> , 2010, 139, 95-97.   | 0.8 | 6         |
| 157 | Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1569-71.  | 1.4 | 6         |
| 158 | Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Circulation Journal</i> , 2013, 77, 2088-2096.   | 0.7 | 6         |
| 159 | Major bleeding risk prediction using Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations in acute coronary syndrome. <i>European Journal of Clinical Investigation</i> , 2015, 45, 385-393.  | 1.7 | 6         |
| 160 | The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. <i>International Journal of Cardiology</i> , 2016, 217, 42-48.   | 0.8 | 6         |
| 161 | Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. <i>Drug Discovery Today</i> , 2017, 22, 1565-1571.  | 3.2 | 6         |
| 162 | Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome. <i>Revista Española De Cardiología (English Ed)</i> , 2020, 74, 765-772.  | 0.4 | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients. <i>Annals of Translational Medicine</i> , 2016, 4, 200-200.   | 0.7 | 6         |
| 164 | Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 1040-1047.   | 1.5 | 6         |
| 165 | Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773. | 1.7 | 6         |
| 166 | The role of tissue plasminogen activator on the progression of the coronary disease. <i>European Heart Journal</i> , 2002, 23, 88.  | 1.0 | 5         |
| 167 | Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. <i>International Journal of Cardiology</i> , 2005, 98, 517-518.   | 0.8 | 5         |
| 168 | Involvement of the $\alpha$ 2C>RETN</i> polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy. <i>Journal of Internal Medicine</i> , 2015, 278, 50-58.   | 2.7 | 5         |
| 169 | Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. <i>Platelets</i> , 2016, 27, 777-783.   | 1.1 | 5         |
| 170 | Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. <i>Circulation Journal</i> , 2016, 80, 605-612.  | 0.7 | 5         |
| 171 | Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. <i>Europace</i> , 2016, 18, 1328-1334.  | 0.7 | 5         |
| 172 | Applicability of the modified CHA <sub>2</sub> DS <sub>2</sub> -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017, 38, e21-e22.  | 1.0 | 5         |
| 173 | Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 4403.  | 1.0 | 5         |
| 174 | Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.                                   | 1.0 | 5         |
| 175 | Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13788.   | 1.7 | 5         |
| 176 | Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Internal Medicine</i> , 2022, 103, 41-49.  | 1.0 | 5         |
| 177 | Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2005, 3, 357-364.   | 1.7 | 4         |
| 178 | Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2005, 58, 934-940.   | 0.4 | 4         |
| 179 | Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 163-166.   | 1.0 | 4         |
| 180 | Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.   | 0.8 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.  | 0.7 | 4         |
| 182 | Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1107-1114.   | 1.8 | 4         |
| 183 | Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. <i>Journal of Clinical Medicine</i> , 2021, 10, 3357.  | 1.0 | 4         |
| 184 | Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease. <i>Minerva Medica</i> , 2019, 110, 410-418.  | 0.3 | 4         |
| 185 | Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. <i>Cardiology Journal</i> , 2018, 25, 151-154.   | 0.5 | 4         |
| 186 | Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787235.                               | 1.1 | 4         |
| 187 | The pharmacogenetics of antiplatelet drugs. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 213-8.   | 2.3 | 4         |
| 188 | Criteria for admitting elderly patients with acute coronary syndrome to critical care units from Spanish hospital emergency departments: a LONGEVO-SCA cohort study. <i>Emergencias</i> , 2019, 31, 154-160.  | 0.6 | 4         |
| 189 | Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.                                 | 1.1 | 4         |
| 190 | Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856222.   | 1.1 | 4         |
| 191 | High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2414-2415. | 1.9 | 3         |
| 192 | Update on Ischemic Heart Disease and Critical Care Cardiology. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 120-126.  | 0.4 | 3         |
| 193 | Strategies for prediction and early detection of atrial fibrillation: present and future. <i>Europace</i> , 2016, 19, euw131.   | 0.7 | 3         |
| 194 | Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 6-12.   | 0.4 | 3         |
| 195 | ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists. <i>REC: CardioClinics</i> , 2019, 54, 165-172.  | 0.1 | 3         |
| 196 | Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.   | 0.8 | 3         |
| 197 | Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 183-188.                | 0.2 | 3         |
| 198 | Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.                                      | 0.9 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIA study. <i>European Journal of Internal Medicine</i> , 2020, 78, 63-68.  | 1.0 | 3         |
| 200 | Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13505.   | 1.7 | 3         |
| 201 | Lone Atrial Fibrillation- A Diagnosis of Exclusion. <i>Current Pharmaceutical Design</i> , 2014, 21, 544-550.  | 0.9 | 3         |
| 202 | Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> , 0, , . | 0.8 | 3         |
| 203 | Estratificaci3n del riesgo hemorr3gico en el s3ndrome coronario agudo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2010, 10, 49-58.   | 0.2 | 2         |
| 204 | N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin in the Evaluation of Acute Chest Pain of Uncertain Etiology. A PITAGORAS Substudy. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 532-538.  | 0.4 | 2         |
| 205 | Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions. <i>Thrombosis and Haemostasis</i> , 2013, 109, 363-365.   | 1.8 | 2         |
| 206 | New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. <i>Molecules</i> , 2016, 21, 284.   | 1.7 | 2         |
| 207 | Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low4moderate risk of stroke?. <i>European Journal of Internal Medicine</i> , 2016, 35, e9-e10.   | 1.0 | 2         |
| 208 | Comentarios a la actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 6-12.  | 0.6 | 2         |
| 209 | Chronic Kidney Disease and Third4Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 295-302.   | 1.0 | 2         |
| 210 | Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 685-686.   | 0.4 | 2         |
| 211 | Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. <i>Cardiology</i> , 2021, 146, 656-666.  | 0.6 | 2         |
| 212 | Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 378-383.   | 0.4 | 2         |
| 213 | Comentarios a la gu3a ESC/EACTS 2020 sobre el diagn3stico y tratamiento de la fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 378-383.   | 0.6 | 2         |
| 214 | Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. <i>Europace</i> , 2022, 24, 4-11.   | 0.7 | 2         |
| 215 | The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. <i>Journal of General Internal Medicine</i> , 2023, 38, 315-323.  | 1.3 | 2         |
| 216 | Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?. <i>Thrombosis Research</i> , 2011, 128, 601-602.  | 0.8 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy. <i>European Journal of Clinical Investigation</i> , 2016, 46, 123-129.  | 1.7 | 1         |
| 218 | Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of <scp>CHADS<sub>2</sub></scp> and <scp>CHA<sub>2</sub></sub><sub>DS<sub>2</sub></sub></scp> <scp>VASc</scp> scores. <i>Internal Medicine Journal</i> , 2016, 46, 583-589. | 0.5 | 1         |
| 219 | Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 806-807.   | 1.8 | 1         |
| 220 | Oral anticoagulation and comorbidities; too many details for clinical practice?. <i>International Journal of Cardiology</i> , 2018, 264, 93-94.   | 0.8 | 1         |
| 221 | Galectin-3 and Î²-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. <i>Scientific Reports</i> , 2019, 9, 6235.  | 1.6 | 1         |
| 222 | Factor XI, much more than an innocent observer. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3172-3173.   | 1.9 | 1         |
| 223 | Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIA Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 316-323.   | 1.0 | 1         |
| 224 | OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .   | 1.4 | 1         |
| 225 | Biomarkers of Necrosis and Myocardial Remodeling. , 2014, , 1-24.   |     | 1         |
| 226 | New Role of Biomarkers in Atrial Fibrillation. , 2015, , 1-33.  |     | 1         |
| 227 | Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. <i>European Journal of Internal Medicine</i> , 2022, 98, 122-124.  | 1.0 | 1         |
| 228 | Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.  | 0.8 | 1         |
| 229 | Relation of Maximal Doses of Atorvastatin to Indices of Inflammation, Thrombogenesis and Angiogenesis in High-Risk Patients with Ischemic Heart Disease. <i>Clinical Science</i> , 2003, 104, 9P-9P.  | 0.0 | 0         |
| 230 | ¿Podemos esperar de los polimorfismos las respuestas a nuestras dudas?. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 1129.  | 0.6 | 0         |
| 231 | Can We Expect Polymorphisms to Answer our Questions?. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq1 1,0,784314,rgBT /Ome   | 0,4 | 0         |
| 232 | Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1419-1431.  | 1.1 | 0         |
| 233 | The complex role of bone turnover biomarkers in cardiovascular diseases. <i>European Journal of Heart Failure</i> , 2013, 15, 709-710.  | 2.9 | 0         |
| 234 | Estratificaci3n pron3stica din3mica en el infarto agudo de miocardio con elevaci3n del segmento ST. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 588.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Dynamic Prognostic Stratification in ST-elevation Myocardial Infarction. Response. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 588.  | 0.4 | 0         |
| 236 | Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology, 2015, 11, 565-583.  | 0.5 | 0         |
| 237 | New Role of Biomarkers in Atrial Fibrillation. , 2016, , 507-539.   |     | 0         |
| 238 | Evaluaci3n de los esquemas de riesgo hemorr3gico HAS-BLED y ORBIT en pacientes con fibrilaci3n auricular no valvular tratados con anticoagulaci3n oral. Revista Espanola De Cardiologia, 2017, 70, 132-133. | 0.6 | 0         |
| 239 | Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. Revista Espanola De Cardiologia (English Ed ), 2017, 70, 132-133.          | 0.4 | 0         |
| 240 | Research update for articles published in EJCI in 2015. European Journal of Clinical Investigation, 2017, 47, 775-788.  | 1.7 | 0         |
| 241 | 115...Plods and lox participate in vascular smooth muscle cell calcification. , 2018, , .   |     | 0         |
| 242 | Are There Gaps in the Evidence on the Treatment of Mild Hypertension in Patients With Low Cardiovascular Risk? Response. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 886.                      | 0.4 | 0         |
| 243 | Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. Expert Review of Precision Medicine and Drug Development, 2020, 5, 331-345.     | 0.4 | 0         |
| 244 | Biomarkers of Necrosis and Myocardial Remodeling. Biomarkers in Disease, 2015, , 659-688.   | 0.0 | 0         |
| 245 | Riesgo emb3lico, riesgo isqu3mico y riesgo hemorr3gico. Revista Espanola De Cardiologia Suplementos, 2019, 18, 3-8.   | 0.2 | 0         |
| 246 | ¿Existen lagunas en la evidencia vinculada al tratamiento de la hipertensi3n leve de bajo riesgo cardiovascular? Respuesta. Revista Espanola De Cardiologia, 2019, 72, 886.                                 | 0.6 | 0         |
| 247 | Influence of the matrix type over the concentration of GDF-15. Journal of Investigative Medicine, 2020, 68, 1402-1404.  | 0.7 | 0         |
| 248 | Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP AF Long-term General Registry. European Journal of Clinical Investigation, 2021, , e13709.                         | 1.7 | 0         |
| 249 | Impact of body mass index on outcomes in European patients with atrial fibrillation: the ESC EHRA EORP Atrial Fibrillation General Long-Term registry (AFGen LT). European Heart Journal, 2020, 41, .       | 1.0 | 0         |
| 250 | Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. Diabetes Research and Clinical Practice, 2022, 184, 109215.  | 1.1 | 0         |
| 251 | Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. Journal of Thrombosis and Thrombolysis, 2022, , 1.                              | 1.0 | 0         |
| 252 | Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?. Revista Espanola De Cardiologia (English Ed ), 2022, , .   | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Predicting heart failure in atrial fibrillation patients: What about using biomarkers?. American Heart Journal, 2022, 251, 32-32. | 1.2 | 0         |